NCR1 and neoplasm: In line with the notion that full activation of resting NK cells requires the coengagement of distinct activating receptors (32, 33), trifunctional NKCEs referred to as antibody-based NK-cell engager therapeutics (ANKET), which coengage NKp46 and CD16A on NK cells and bind an antigen on tumor cells (NKp46/CD16A/TA), have been produced.